Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.16 -0.40 (-2.45%)

Streaming Delayed Price Updated: 12:43 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 07, 2024

Via Benzinga

Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 06, 2024

Via Benzinga

Why Summit Therapeutics Stock Is Trading 8% Higher Monday ↗

June 03, 2024

Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.

Via Benzinga

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

June 03, 2024

From Summit Therapeutics Inc.

Via Business Wire

Day Trading During A Slow Holiday Week ↗

June 01, 2024

We made it to the end of a holiday-shortened week. It was a slow week of day trading, but I’m happy with how it finished. Let’s break it down in today’s recap.

Via Talk Markets

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership ↗

June 01, 2024

Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in...

Via Talk Markets

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

June 01, 2024

From Summit Therapeutics Inc.

Via Business Wire

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

May 31, 2024

From Summit Therapeutics Inc.

Via Business Wire

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 31, 2024

Via Benzinga

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study ↗

May 31, 2024

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 31, 2024

Via Benzinga

Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

May 31, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 31, 2024

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning!

Via InvestorPlace

Marvell Technology Posts Weak Q1 Results, Joins MongoDB, Dell Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 31, 2024

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2024

From Summit Therapeutics Inc.

Via Business Wire

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

May 30, 2024

From Summit Therapeutics Inc.

Via Business Wire

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 28, 2024

Via Benzinga

Why Summit Therapeutics Stock Is Sinking Today ↗

May 28, 2024

Investors continue to react negatively to recent late-stage results for Summit's experimental cancer therapy.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 27, 2024

Via Benzinga

Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 24, 2024

Via Benzinga

Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗

May 24, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 24, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 24, 2024

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Via InvestorPlace

Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 24, 2024

Via Benzinga

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday ↗

May 07, 2024

Via Benzinga

SMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024 ↗

May 01, 2024

Summit Therapeutics just reported results for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.